Articles On Orthocell (ASX:OCC)

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Regenerative medicine company Orthocell (ASX:OCC) has entered into an exclusive patent and trademark license agreement and an exclusive distribution and supply agreement with BioHorizons Implant Systems.

It wasn’t exactly a red-letter day for the market as a whole, though – the ASX adding less than 0.5%, in spite of a beckoning smile from Wall Street overnight. Aussie markets opened to the news that The Nasdaq had posted a 1.62% gain, follo...

Avita Medical makes spray on skin for burns and soft tissue injuries HITIQ’s concussion tech is popular for athletes and sports teams PainChek’s smartphone app can tell if babies or older Aussies are in pain There’s a plethora of biotech...

Orthocell’s (OCC) nerve reconstruction trial demonstrates the early recovery of muscle function in paralysed upper limbs The news follows the completion of Orthocell’s Remplir nerve reconstruction study on patients who suffered traumatic n...

Orthocell’s nerve reconstruction trial shows encouraging results Neuroscientific gets ethics approval to commence early-phase clinical trial Orthocell demonstrates encouraging trial results Orthocell (ASX:OCC) jumped 7% this morning after...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Managing director Paul Anderson said, “Remplir is the first of its kind biological scaffold designed by an Australian team of researchers to mimic the outer layer of the peripheral nerve and facilitate high-quality nerve repair."...

Regenerative medicine company Orthocell (OCC) receives regulatory approval for its Remplir peripheral nerve repair device to be introduced into the Australian nerve repair and regeneration market The approval includes Remplir on the Austra...

Orthocell’s Remplir device gets approval for the Australian Register of Therapeutic Goods (ARTG) Argenica’s study on lead drug ARG-007 is published in a medical journal The ASX 200 Health Index (XHJ) is trading lower by 0.50% at the time...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Regenerative medicine company Orthocell (ASX:OCC) has provided a US market entry update for the Striate+ premium dental membrane.

Orthocell (OCC) is set to scale up the manufacturing capacity of its Striate+ premium dental membrane Orthocell says it’s been actively preparing to increase its manufacturing capacity to greater than 100,000 units per year after receiving...

It has also received approvals to upgrade its existing facility and scale-up Striate+™ manufacturing capacity to more than 100,000 units per year. 

The company is focused on regenerating mobility for patients by developing innovative products for the repair of a variety of bone and soft tissue injuries.

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

“This is exciting research that opens up potential for novel treatments addressing significant unmet medical needs and we will explore these development options alongside our nerve repair applications."

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

Ultimately, the new data supports the breadth of Orthocell’s cornerstone CelGro™ platform, with positive results recorded across nerve, tendon and bone repair studies.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The ASX had another day of solid gains, hitting a three week high with tech and resources leading the charge. The ASX 200 rose 1.25%, closing at 7,405 and while all sectors were in the green, resources and tech both were the best – gaining...

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success. At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%. Orthocell is developing new medical devices and...

The orthopaedic cell therapy company is in its strongest position yet to launch into the lucrative US market, worth an estimated US$4-5 billion.

Orthocell’s (OCC) latest study results reveal OrthoATI is more effective than steroid injection for treating rotator cuff tendon tears The announcement follows a randomised, multicentre, controlled rotator cuff tendon clinical study Patien...

The ASX finished 0.67% higher, marking the best performance by the Australian bourse since early October. Almost all sectors finished higher with energy and tech – two sectors under siege in recent weeks – recording gains of 2.07% and 1.9%...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Regenerative medicine company Orthocell (ASX:OCC) has announced that the Autologous Tenocyte Injection rotator cuff tendon study database has been locked.

“This is an important development milestone for OrthoATI® and the company and I am delighted to have reached this pivotal stage of the study,” says MD.

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

Turn on, tune in and don’t drop out. The push to develop psychedelic drugs is gaining momentum, but not quite in the way the 1960s counter-culture figure Dr Timothy Leary intended. The late Harvard psychologist strongly advocated the use of...

Orthocell’s CelGro platform forms the basis of a specialised collagen ‘rope’ that could help reconstruct the anterior cruciate ligament, a strong band of tissue linking the thigh and shin bones that can rupture during athletic activity.

The biggest director trade on the ASX in the past fortnight came from one of Australia’s most famous pub barons – Bruce Mathieson of Endeavour Group (ASX:EDV). Mathieson is 63rd on the Top 22 rich list with a net worth of $1.54 billion. End...

The regenerative medicine company could be on the verge of developing the first off-the-shelf biological device used to treat ACL injuries, a market linked to a growing health economic burden.

The ASX 200 health stocks index (XHJ) has lifted by 0.19% at the time of writing, compared to the broader ASX 200 index which fell by 0.70%. The cancer and fibrosis focused company, Amplia Therapeutics (ASX:ATX), has completed the design fo...

Highlights  The ASX 200 closed marginally higher on Tuesday despite the Reserve Bank of Australia (RBA) announced its plans to start reducing the bond buying. The ASX 200 closed 0.02% higher at 7,530.30 after rallying towards the close...

The company’s pre-clinical studies have shown at a microscopic level that CelGro® produces superior nerve repair and return of muscle function in severed peripheral nerves when compared to the traditional (direct suture) repair method.

Highlights The ASX 200 was trading flat at 7,536.9 by lunchtime. A-VIX, which shows the volatility of the Australian share market, is trading 4.1% down at 10.88. Aussie Broadband plans to raise AU$120 million for the purpose of accele...

ShareCafeAustralia… One Hour In… ASX200 down 74 ASX200 down 24 points (0.3%) to 7504.   Reserve Bank interest rate decision due at 2.30pm.   Aussie Broadband (TH);  Trading Halt for $120m cap raising. Amcor (-1.1%); ex div 15.93c.  Trading...

Regenerative medicine company Orthocell (ASX:OCC) has announced that new patents have been granted in Canada and Hong Kong for its novel CelGro collagen medical device platform for soft tissue regeneration applications.

Regenerative medicine company Orthocell (ASX:OCC) has announced that the last patient in the Autologous Tenocyte Injection rotator cuff tendon study has completed their 12-month follow-up visit.

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

“This is an important development milestone for Ortho-ATI and the company, representing the first randomised controlled trial for a tendon cell therapy to be completed for this indication globally,” says MD.